GlassScriptPhysician profile
Shannon Bednarz
NPI 1023519246
$1,181.54
in general payments reported to CMS, 2019-2025
14 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $141 · 2023: $329 · 2024: $304 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.96 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $483.97 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Janssen Scientific Affairs, LLC | $146.98 | 2021-2022 | |
| Abbvie INC. | $128.75 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $106.49 | 2023 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $82.78 | 2024-2025 | Dupixent |
| Convatec INC. | $39.92 | 2025 | |
| Galderma Laboratories, L.P. | $33.15 | 2025 | Nemluvio |
| Lilly USA, LLC | $31.16 | 2021 | |
| Almirall LLC | $25.69 | 2024 | Seysara |
| Novartis Pharmaceuticals Corporation | $24.55 | 2024 | |
| Incyte Corporation | $24.20 | 2022 | |
| Novo Nordisk INC | $20.80 | 2021 | |
| Boston Scientific Corporation | $18.81 | 2023 | Superion Indirect Decompression System |
| Allergan, INC. | $14.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Bednarz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.